Retatrutide

Mean bodyweight change at week 80 was -11.9% (4 mg), -16.8% (9 mg), and -18.8% (12 mg) versus -5.1% with placebo; Estimated treatment differences versus placebo were -6.9%, -11.8%, and -13.8% for 4 mg, 9 mg, and 12 mg respectively (p<0.0001 for all); Gastrointestinal adverse events such as diarrhoea and nausea were more frequent with retatrutide than placebo; Permanent discontinuation due to adverse events or death was more frequent with retatrutide 9 mg (12%) and 12 mg (8%) than 4 mg (4%) or placebo (5%)

GLP-1 and GIP are incretin hormones that increase insulin secretion, and their receptor agonists are used for diabetes and obesity.; Approved GLP-1 receptor agonists for diabetes include liraglutide, semaglutide, and injectable dulaglutide; liraglutide and semaglutide are approved for obesity.; Tirzepatide is a combined GLP-1/GIP receptor agonist approved for type 2 diabetes, obesity, and obesity with weight-related comorbidities such as obstructive sleep apnea.; Peptide fatty acid acylation extends half-life by co-opting albumin as a fatty acid transporter, and nausea/vomiting necessitate sequential dose escalation over weeks.

Retatrutide reduced HbA1c by 1.69% to 1.94% versus 0.81% with placebo, with treatment differences of -0.88% to -1.12% (all p<0.0001).; Body weight decreased by 11.5% to 15.3% with retatrutide versus 2.6% with placebo.; Most adverse events were mild-to-moderate gastrointestinal events that subsided over time; discontinuations due to adverse events were 2-5% with retatrutide and 0% with placebo.; No severe hypoglycemia was reported; two deaths occurred in the retatrutide 4 mg group, both unrelated to the study drug.

Retatrutide is a triple agonist of GIP, GLP-1, and glucagon receptors.; The program includes two basket trials (TRIUMPH-1 and -2) with nested OSA/OA protocols, one CVD-focused trial (TRIUMPH-3), and one stand-alone OA trial (TRIUMPH-4).; Type I error rate is controlled at 0.05 across weight management and basket trials.; The design allows concurrent evaluation of retatrutide for obesity, OSA, and knee OA.

Female mice showed more severe liver injury (elevated ALT and hepatic triglycerides) after a single fructose binge than male mice.; The novel 31-day feeding model significantly increased body weight, ALT, hepatic triglycerides and cholesterol, and hepatic inflammatory markers in both sexes versus chow-fed controls.; Hepatic gene expression profiles of treated mice correlated with human MASH in children and adults.; Retatrutide intervention significantly improved steatohepatitis markers in female mice in this shortened model.

Mean HbA1c reduction of -1.04% (95% CI -1.42 to -0.67) with retatrutide treatment; Weight loss reaching up to -24.2%; Glycemic benefits were dose-dependent, with lower doses (≤8 mg) showing greater HbA1c reduction (-1.39%) than higher doses (≥12 mg, -0.65%); Secondary analyses suggested possible renoprotective effects via reduced albuminuria; safety was mainly gastrointestinal adverse events

Retatrutide 8 mg (pooled) led to a 26.1% reduction in total fat mass, significantly greater than placebo (4.5% reduction).; Retatrutide 4 mg and 12 mg also significantly reduced fat mass compared to placebo (15.2% and 23.2% reductions, respectively).; Adverse events were similar across groups, with gastrointestinal events most common and no deaths reported.; Lean mass loss proportion was similar to other obesity treatments, indicating no disproportionate lean mass loss with retatrutide.

Obesity reduces life expectancy by 5-20 years and imposes a global economic burden of USD 2 trillion annually.; GLP-1 receptor agonists achieve 15-25% mean weight loss, reduce major adverse cardiovascular events by 20%, and lower T2D incidence by 72%.; Emerging therapies like oral GLP-1 agonists and triple-receptor agonists may improve tolerability and muscle preservation.; Challenges include high costs, supply shortages, gastrointestinal side effects, and weight regain after discontinuation.

What is Retatrutide?

Retatrutide (LY3437943) is a synthetic peptide designed as a triple agonist at the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. Its mechanism of action integrates complementary metabolic effects: GLP-1 receptor activation enhances insulin secretion and del

How does Retatrutide work?

Triple GIP/GLP-1/glucagon receptor agonist in phase 3 trials showing the largest weight reductions of any incretin therapy to date.

What is the research status of Retatrutide?

Retatrutide is currently classified as clinical trials, with 204 research references on record. This is for research purposes only and is not medical advice.